43 results about "Caplet Dosage Form" patented technology

The invention relates to a method for detecting light liquid paraffin residue in a soft capsule dosage form, which adopts high performance liquid chromatography based on an evaporative light-scattering detector for detection, and comprises the following steps: (1) setting conditions of the high performance liquid chromatography; (2) dissolving an n-octadecane reference substance in dichloromethane to prepare n-octadecane reference substance linear solutions with different gradient concentrations between 28g / mL and 210g / mL, drawing detection results of the high performance liquid chromatography into a standard curve, and fitting to obtain the standard curve; (3) taking the solution in a plurality of soft capsules, putting the solution in a measuring flask, adding dichloromethane for dissolving, and filtering with a 0.22 m filter membrane for later use; and (4) sampling the test solution, then sampling the n-octadecane reference substance solution, comparing the logarithm values of the chromatogram peak areas of the test solution and the reference substance solution, and calculating the concentration of n-octadecane in the sample by an external standard method, thereby obtaining the residual concentration of light liquid paraffin.

The invention provides a Milsartan potassium capsule and a preparation method thereof, the Milsartan potassium capsule is prepared by filling a Milsartan potassium micro-tablet into a hollow capsule, the compliance of a patient is improved, and compared with a common tablet, the micro-tablet can improve the dissolution rate and increase the contact area with gastrointestinal mucosa after oral administration, so that the bioavailability of a medicine can be improved, and the bioavailability of the medicine is improved. In addition, the micro-tablets are filled into hollow capsules, so that the exposure of the tablets can be reduced, the influence of moisture can be reduced, and the stability of the medicines can be improved.

The invention discloses a yunaconitine derivative and application of the yunaconitine derivative in preparation of hypoglycemic and antioxidant drugs, the yunaconitine derivative has a chemical structure as shown in a formula 1a or 1b, and the invention further provides application of the yunaconitine derivative in preparation of PTP1B inhibitors. The dosage form of the medicine is selected from at least one of a tablet, a capsule, a granule, a dripping pill, a suspension, syrup, an enteric-coated preparation, an emulsion suspension and an injection. The yunaconitine derivative disclosed by the invention is high in bioavailability and clinical use value, provides a candidate lead compound for research and development of novel preparations of hypoglycemic and antioxidant drugs, and has potential application value in the fields of hypoglycemic and antioxidant targeted drugs, probe design and fluorescent biomarkers.

The present disclosure relates to suspension-based pharmaceutical formulations for cold and flu medications, and more specifically to high-concentration suspension formulations and soft gel capsule dosage forms having reduced size, as well as methods of preparing the suspension formulations and soft gel capsules thereof.

The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation. The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-CL® tablet. Moreover, the extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration for patients who have difficulty swallowing tablets or capsules, e.g., paediatric patients or geriatrics.

The invention provides a candesartan cilexetil capsule and a preparation method thereof, and the candesartan cilexetil capsule is characterized in that each capsule contains candesartan cilexetil, lactose, corn starch, hydroxypropyl cellulose, carboxymethyl cellulose calcium, polyethylene glycol 8000 and magnesium stearate. According to the candesartan cilexetil capsule provided by the invention, the problem of stability of candesartan cilexetil is solved, the possibility of crystal transformation of common tablets in a tabletting process is reduced, and the characteristic dissolution curve of a final product is similar to that of a reference preparation; the preparation method is simple in process route, the fluidized bed one-step granulation method enables the loss to be less, the product yield is higher, and the industrial mass production cost is reduced.

The invention discloses a multi-system drug release system for Parkinson's disease treatment, which is a capsule prepared from the following drug release systems and auxiliary materials in percentage by weight: 58.0 to 64.1 percent of an entacapone drug release system, 28.5 to 31.5 percent of a levodopa drug release system, 7.6 to 8.4 percent of a carbidopa drug release system and 0.5 to 1.5 percent of talcum powder, the drug-loaded pellet of the entacapone drug release system comprises a first pellet core, an isolation layer and an enteric layer which are sequentially arranged from inside to outside, and the drug-loaded pellet of the levodopa drug release system comprises a second pellet core and a first modification layer which are sequentially arranged from inside to outside, the drug-loaded pellet of the carbidopa drug release system comprises a third pellet core and a second modification layer which are sequentially arranged from inside to outside. The multi-system drug release system can realize independent and long-term slow release of three different active components without mutual interference. According to the method, a multi-system drug release system can be prepared with high loading capacity, and the problem of large dosage of drugs is effectively solved.

A transient oil-in-simethicone emulsion for oral administration wherein 5 simethicone is present from 50% to 80% by weight of the emulsion. Also described is the process for the preparation of the transient oil-in-simethicone emulsion and capsule dosage form.

The invention discloses a defoaming agent adaptive to a digestive tract environment, and a preparation method and application thereof, and relates to the technical field of digestive tract examination assistance. The defoaming agent comprises simethicone, hyaluronidase, bromelain and sodium bicarbonate, and the preparation form is a capsule in which a quick-release drug-loading unit and an enteric drug-loading unit are mixed. The preparation method comprises the following steps: preparing the quick-release drug-loading unit, preparing the enteric drug-loading unit, and mixing and encapsulating. The defoaming agent is orally taken 25-35 minutes before gastroscopy, a closed loop of gastric acid neutralization, thick mucus degradation and foam removal effects can be formed, the problem of poor defoaming caused by mucus wrapping foam is solved, the field of view in the stomach is optimized, and the accuracy of stomach disease diagnosis is guaranteed.

The invention discloses a composition for treating idiopathic pulmonary fibrosis and a preparation method and application thereof. The composition for treating idiopathic pulmonary fibrosis is formed by mixing baicalin nanocrystals and ambroxol hydrochloride, and is prepared into various medical dosage forms through a conventional method, including oral preparations such as tablets, capsules, granules or oral liquid. The composition can remarkably improve rat idiopathic pulmonary fibrosis caused by bleomycin sulfate, relieve the symptom of rat pulmonary fibrosis by reducing the inflammatory factor content, the total protein content and collagen deposition, and improve the oral bioavailability of the monomer baicalin. The traditional Chinese medicine composition is suitable for preventing and treating idiopathic pulmonary fibrosis.

The present disclosure relates to compositions comprising coenzyme Q10 and a water soluble excipient, and methods for treating coenzyme Q10 deficiency in a subject, including oral administration of the composition. The composition can be in a solid or liquid dosage form, such as a ball, a granule, a tablet, a capsule, an oral solution and a soft capsule, and is used for oral administration. The composition may comprise coenzyme Q10 and a binder mixture coated on a tablet core, wherein the tablet core comprises a sugar, microcrystalline cellulose, or a mixture thereof. The composition is an immediate release formulation having high solubility in an aqueous medium.

The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

The present invention relates to a pharmaceutical composition comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizers in the form: A) an aqueous solution for intravenous administration comprising a sodium salt or lysine salt of ibuprofen, acetaminophen and preferably one or more cyclodextrins; or B) an aqueous solution for intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins; or C) a composition for oral administration comprising acetaminophen and cyclodextrin wherein the composition is in the form of i) an effervescent tablet or effervescent granule, or ii) an oral suspension or syrup or oral solution, or iii) a soft capsule.

The invention discloses an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems of low bioavailability, large administration dosage, high side effect risk and the like of ibrutinib, the invention provides an ibrutinib pharmaceutical composition and preparation as well as a preparation method and application thereof, the pharmaceutical composition comprises an active substance ibrutinib monolauryl sulfate, a filler, a release regulator and / or other auxiliary materials, the other auxiliary materials comprise at least one of a lubricant, a disintegrating agent and a flow aid; the preparation is a capsule or a tablet. According to the preparation of the ibrutinib monolaurinol sulfate composition prepared by adopting granulation or direct mixing, the bioavailability is greatly improved, and the dosage is greatly reduced under the condition that the blood exposure is basically unchanged; meanwhile, relatively stable blood concentration can be maintained, and the preparation has the advantages of small toxic and side effects, convenience in taking, high bioavailability and the like.

The invention discloses application of kaempferol in preparation of a medicine for treating echinococcosis, and relates to the technical field of biological medicines. The invention further discloses a medicine for treating echinococcosis. The medicine comprises kaempferol. The dosage form of the medicine is any pharmaceutically acceptable dosage form, and comprises, but not limited to, tablets, granules, capsules, pills, oral liquid, injections and lipidosome. The invention finds that the kaempferol has the effect of killing the protoscolex of the echinococcosis, can obviously inhibit the growth of the tissue of the echinococcosis, has no obvious cytotoxicity in effective concentration and no influence on liver and kidney functions, can be used as a safe and effective medicine for treating echinococcosis, and has a relatively great clinical application value.

This invention relates to an ionic amphiphilic bioporphyrin, its preparation method, and its application, belonging to the field of pharmaceutical technology. The preparation method of the ionic amphiphilic bioporphyrin of this invention includes the following steps: stirring and reacting heme with an alkaline solution to obtain a dispersion; adding an acidic solution to the obtained dispersion to adjust the pH to 4-11, thereby obtaining the ionic amphiphilic bioporphyrin. This invention combines the ionized modified amphiphilic bioporphyrin with alkaline excipients and prepares it into an enteric-coated capsule dosage form, ensuring its stability in gastric acid. Upon reaching the intestine, it achieves effective release and creates a suitable alkaline microenvironment for the dissolution of ionic heme, thereby improving the solubility of heme derivatives in the intestine and oral uptake efficiency.

The present disclosure relates to suspension-based pharmaceutical formulations for cold and flu medications, and more specifically to high-concentration suspension formulations and soft gel capsule dosage forms having reduced size, as well as methods of preparing the suspension formulations and soft gel capsules thereof.

The invention relates to a cabazitaxel composition and application of the cabazitaxel composition. Embodiments provide a composition comprising cabazitaxel and at least one lipid and / or cougsterol, and / or a cougsterol derivative, and / or sodium cholesterol sulfate, in the form of a tablet or capsule, and administering the composition to a subject.

A rupatifen fumarate capsule and a preparation method therefor. The capsule comprises a capsule shell and contents enclosed by the capsule shell. The capsule has excellent formulation performance and good stability. During preparation and long-term storage, there is no reduction in drug substance content and no significant increase in impurity content. The dissolution rate is fast, and the stability is good, thereby ensuring the quality of the final formulation and the safety and effectiveness of clinical use.

Described herein are stable solid oral capsule dosage form comprising dabigatran etexilate or pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient, wherein said dosage form has controlled and reduced levels of N-nitroso dabigatran (NDAB). Also, disclosed are methods of manufacturing such stable solid capsule oral dosage forms of dabigatran etexilate and its pharmaceutically acceptable salt.

The present invention relates to a dry suspension containing lansoprazole and sodium bicarbonate and a preparation method thereof. By strictly controlling the dosage of sodium bicarbonate and the ratio of each component, the prepared dry suspension has good acid resistance and stability. The active ingredient sodium bicarbonate in the product can quickly neutralize gastric acid, thereby relieving symptoms such as excessive gastric acid and stomach pain. After neutralizing gastric acid, it can reduce the degradation of the drug by gastric acid, improve the stability of lansoprazole in the human gastric environment, ensure the rapid dissolution and high bioavailability of this product in the stomach, so as to achieve the purpose of rapid onset. At the same time, during the research process of the present invention, it was unexpectedly found that through a specific mixing sequence, not only can the stability and mixing uniformity of the product be further improved, but also a better taste masking effect can be achieved. In addition, being prepared as a dry suspension is particularly suitable for the elderly, children and patients with difficulty in swallowing, and has clinical compliance that cannot be compared with tablets or capsules of the same specification. The preparation method of this product is simple, highly operable, and has great clinical significance.

The application discloses a pharmaceutical composition containing abiraterone acetate and a preparation method and application thereof. An excipient of the pharmaceutical composition contains at least one oil phase, at least one emulsifier and at least one co-emulsifier. The pharmaceutical composition can significantly improve bioavailability and stability of a preparation. The pharmaceutical composition can be further prepared into a capsule.

A racanisodamine capsule with high dissolution rate and fast disintegration belongs to the technical field of medicine preparation, and through the innovation of narrow distribution micronization of active ingredients, synergistic compatibility of novel auxiliary materials, capsule type adaptation process and the like, the prepared racanisodamine capsule has the dissolution rate of more than or equal to 95% within 30 min and the accelerated test dissolution rate of more than or equal to 92% within 12 months, the auxiliary materials are plant-derived or degradable ingredients, and the process energy consumption is reduced by more than 20%. The invention expands the dosage form applicable population, further improves the drug effect and safety, is energy-saving and environment-friendly, and conforms to the green pharmaceutical trend.

The invention provides a compound omeprazole capsule and a preparation method thereof. The compound omeprazole capsule is prepared from 20 mg of omeprazole, 1100 mg of sodium bicarbonate, 25-35 mg of croscarmellose sodium and 5-15 mg of stearic acid sodium fumarate according to a prescription per unit. The invention further provides a preparation method of the compound omeprazole capsule. The compound omeprazole capsule which takes effect quickly and can inhibit omeprazole from being degraded by gastric acid is obtained through premixing, total mixing and filling. According to the technical scheme, the omeprazole sodium bicarbonate capsule which is high in initial dissolution rate (10-15 min) and faster in effect taking is obtained by screening the prescription composition and dosage of the compound omeprazole capsule and simplifying the preparation process, and due to the fact that the preparation process is convenient and fast, the production cost and the technical difficulty are reduced, and industrial large-scale production is better facilitated.

At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are porous solids of compacted drug and excipient powders. Upon ingestion, physiological fluid percolates the open pores, and the dosage form disintegrates and the drug dissolves. Because the pores in the compacted solids are not well connected, however, fluid percolation generally is not uniform, and the drug release rate is difficult to predict and control. To overcome such limitations, therefore, herein a structured solid dosage form is disclosed. The structured solid dosage form comprises a structural assembly of one or more repeatably arranged, extruded structural elements. The elements comprise segments separated and spaced from adjoining segments by free spacings defining one or more substantially interconnected free spaces, or channels, in the dosage form through which a physiological fluid may percolate. The disclosed dosage form enables more predictable drug release rates, and can be readily manufactured by 3D-printing.

The application belongs to the technical field of effective components of Chinese medicinal materials, and particularly relates to application of Caraphenol A in preparation of xanthine oxidase inhibiting drugs. 42 H 28 O9, the Caraphenol A can be prepared into drug dosage forms suitable for clinical use, including injection, granules, capsules, tablets, powders, drop pills, sustained-release preparations, and has the action of significantly inhibiting xanthine oxidase activity.

The invention provides a fenerenone capsule and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The finerenone capsule provided by the invention is prepared from the following components: finerenone, a carrier, a filling agent and a disintegrating agent, the carrier is selected from at least one of hydroxypropyl methylcellulose E3 and hydroxypropyl methylcellulose E5; the carrier is divided into a slurry preparation carrier and a granulation carrier; the mass ratio of the granulation carrier to the slurry preparation carrier is (12-30): 1. The fenerenone capsule prepared by the invention has the advantages of uniform particle distribution and stable release. Compared with tablets, the capsule has the advantages that the exposure time of particles and tablets is shortened, coating is avoided technically, and the influence of moisture and a coating layer is avoided to the greatest extent.

The invention relates to a lenalidomide medicine solid dispersion and a preparation method thereof, the solid dispersion comprises 40% of lenalidomide and 60% of a water-soluble carrier, and the water-soluble carrier is povidone; the invention also provides a lenalidomide capsule and a preparation method thereof. The lenalidomide pharmaceutical composition provided by the invention is large in drug loading capacity, and a prepared solid preparation is high in bioavailability, good in solubility and stable and controllable in quality; the preparation method is simple in process, good in reproducibility, high in operability and suitable for large-scale production.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.